COMMUNIQUÉS West-GlobeNewswire

PhaseBio Launches Roadshow for Initial Public Offering

08/10/2018 - 13:00

MALVERN, Pa. and SAN DIEGO, Oct. 08, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (“PhaseBio”), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies [...]

Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies

08/10/2018 - 13:00

Collaboration Focuses on Four Genetic Disorders: Pompe, Fabry, CDKL5 and One Additional Undisclosed Rare Metabolic Disorder Combines Amicus Expertise in Protein Engineering with Penn’s AAV Vector Technology, [...]

Cancer Genetics and Cellaria Partner on Precision Medicine Tools

08/10/2018 - 13:00

Collaboration focused on developing pharmacology models to support biopharma R&D RUTHERFORD, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno [...]

Recro Pharma Announces PDUFA Date for IV Meloxicam

08/10/2018 - 13:00

PDUFA Date Set for March 24, 2019 MALVERN, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and [...]

Inspire Medical Systems, Inc. Announces First Implant of New Sensing Lead in Europe

08/10/2018 - 13:00

MINNEAPOLIS, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]

Akcea Announces Changes to Board of Directors

08/10/2018 - 13:00

Dr. Damien McDevitt replaces Dr. Stanley Crooke on Akcea Board of Directors The change enhances focus on global approval and commercialization of TEGSEDI™ (inotersen) BOSTON, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akcea [...]

Transactions under Novozymes’ stock buyback program

08/10/2018 - 12:54

Please read the full announcement in the attached PDF Attachment 2018_57_Stock_Buybackprogram_EN

Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018

08/10/2018 - 12:30

XERAVA Demonstrated Efficacy in Treating Secondary Bacteremia in Patients with Complicated Intra-Abdominal Infections in Post-Hoc Analysis of Phase 3 Clinical Trials TP-6076 Demonstrated Favorable Pharmacokinetic and [...]

OraSure Technologies Earnings Conference Call Invitation

08/10/2018 - 12:00

2018 Third Quarter Earnings Conference Call Wednesday, November 7, 2018, 5:00 p.m. ET BETHLEHEM, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings [...]

Arrayit Corporation Aces Three Consecutive Rounds of Proficiency Testing with the College of American Pathologists

08/10/2018 - 11:30

Sunnyvale, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, reports that its clinical team aced three consecutive rounds of blinded-specimen [...]

Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2019

08/10/2018 - 11:30

The Annual General Meeting of 2018 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the Company, who each shall elect [...]

AB Science announces the publication of a previously unknown mechanism linked to the progression of ALS and that further reinforces the rationale why masitinib might be protective in ALS

08/10/2018 - 08:48

Paris, October 8, 2018, 8.30am Research led by an international academic team reveals a novel pathogenic mechanism for ALS that can be therapeutically targeted by masitinib Results published in the Journal of Clinical [...]

AB Science la publication d'un mécanisme jusque-ici inconnu en lien avec la progression de la sclérose latérale amyotrophique (SLA) et qui corrobore l'effet protecteur du masitinib dans la SLA

08/10/2018 - 08:48

Paris, 8 octobre 2018, 8h30 Des recherches menées par une équipe universitaire internationale révèlent un nouveau mécanisme pathogène de la SLA pouvant être ciblé thérapeutiquement par le masitinib Les résultats publiés [...]

RAMSAY GENERALE DE SANTE : OPA CAPIO

08/10/2018 - 08:16

PRESS RELEASE THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, OR SOUTH AFRICA. THE OFFER IS NOT BEING MADE TO (AND ACCEPTANCES [...]

RAMSAY GENERALE DE SANTE : OPA CAPIO

08/10/2018 - 08:16

COMMUNIQUE DE PRESSE LE PRESENT COMMUNIQUE DE PRESSE NE PEUT ETRE, DIRECTEMENT OU INDIRECTEMENT, DISTRIBUE OU PUBLIE EN AUSTRALIE, CANADA, HONG KONG, JAPON, NOUVELLE ZELANDE, OU AFRIQUE DU SUD. L'OFFRE N'EST PAS FAITE [...]

Akers Biosciences Announces a Leadership Change, Strategic Update, Legal Settlement and an AIM Update

08/10/2018 - 08:00

THOROFARE, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces a leadership change [...]

Rule 2.9 Announcement

08/10/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 8 October 2018 [...]

Surrender of Share Options

08/10/2018 - 08:00

Summit Therapeutics plc (‘Summit’ or the ’Company’) Surrender of Share Options Oxford, UK, and Cambridge, MA, US, 8 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic [...]

Frost & Sullivan gives award for best innovation in the cosmetics sector to Bio-on

08/10/2018 - 08:00

Minerv Bio Cosmetics, the 100% natural bioplastic microspheres biodegradable in soil and water, are named the year’s most innovative biobased product in the cosmetics sector. Frost & Sullivan finds that “Bio-On is [...]